Back to all studies
CompletedNCT02918318

Fixed Doses of Intranasal Esketamine for treatment-resistant depression

This study is completed in Japan. It is testing fixed Doses of Intranasal Esketamine for treatment-resistant depression.

DepressionDrugFrom 20 Years to 64 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Intranasal esketamine (28 mg) may be useful for adults experiencing depression.

What would participation involve?

Participants may receive Intranasal esketamine (28 mg), attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Japan.

Who is it mainly for?

This study appears to be mainly for adults with depression.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: December 12, 2016
Recruitment status
Completed
Enrollment listed in the registry
202
Sponsor
Janssen Pharmaceutical K.K.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Japan
Age range
From 20 Years to 64 Years
Official registry ID
NCT02918318
Official title
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Japan · 43 sites
  • Akita
    Akita
    Site status: Not listed — confirm with the team
  • Fukui-shi
    Fukui-shi
    Site status: Not listed — confirm with the team
  • Fukuoka
    Fukuoka
    Site status: Not listed — confirm with the team
  • Gunma
    Gunma
    Site status: Not listed — confirm with the team
  • Hachinohe-shi
    Hachinohe-shi
    Site status: Not listed — confirm with the team
  • Hachioji-shi
    Hachioji-shi
    Site status: Not listed — confirm with the team
  • Hirakata
    Hirakata
    Site status: Not listed — confirm with the team
  • Hiratsuka-shi
    Hiratsuka-shi
    Site status: Not listed — confirm with the team
  • Hokkaido
    Hokkaido
    Site status: Not listed — confirm with the team
  • Ibaraki
    Ibaraki
    Site status: Not listed — confirm with the team
  • Ichikawa
    Ichikawa
    Site status: Not listed — confirm with the team
  • Kanzaki-gun
    Kanzaki-gun
    Site status: Not listed — confirm with the team
  • Karatsu
    Karatsu
    Site status: Not listed — confirm with the team
  • Kashihara
    Kashihara
    Site status: Not listed — confirm with the team
  • Kawasaki
    Kawasaki
    Site status: Not listed — confirm with the team
  • Kita-Azumi
    Kita-Azumi
    Site status: Not listed — confirm with the team
  • Kita-ku
    Kita-ku
    Site status: Not listed — confirm with the team
  • Kitakyushu
    Kitakyushu
    Site status: Not listed — confirm with the team
  • Kobe
    Kobe
    Site status: Not listed — confirm with the team
  • Kochi
    Kochi
    Site status: Not listed — confirm with the team
  • Kodaira
    Kodaira
    Site status: Not listed — confirm with the team
  • Komoro-shi
    Komoro-shi
    Site status: Not listed — confirm with the team
  • Kumamoto
    Kumamoto
    Site status: Not listed — confirm with the team
  • Kure
    Kure
    Site status: Not listed — confirm with the team
  • Kurume-shi
    Kurume-shi
    Site status: Not listed — confirm with the team
  • Kyoto
    Kyoto
    Site status: Not listed — confirm with the team
  • Maizuru
    Maizuru
    Site status: Not listed — confirm with the team
  • Morioka
    Morioka
    Site status: Not listed — confirm with the team
  • Nagakute
    Nagakute
    Site status: Not listed — confirm with the team
  • Nagasaki
    Nagasaki
    Site status: Not listed — confirm with the team
  • Okayama
    Okayama
    Site status: Not listed — confirm with the team
  • Okinawa
    Okinawa
    Site status: Not listed — confirm with the team
  • Osaka
    Osaka
    Site status: Not listed — confirm with the team
  • Sapporo
    Sapporo
    Site status: Not listed — confirm with the team
  • Setagaya-ku
    Setagaya-ku
    Site status: Not listed — confirm with the team
  • Shibuya-ku
    Shibuya-ku
    Site status: Not listed — confirm with the team
  • Shinjuku
    Shinjuku
    Site status: Not listed — confirm with the team
  • Shinjuku-ku
    Shinjuku-ku
    Site status: Not listed — confirm with the team
  • Takatsuki-shi
    Takatsuki-shi
    Site status: Not listed — confirm with the team
  • Toyoake
    Toyoake
    Site status: Not listed — confirm with the team
  • Ube
    Ube
    Site status: Not listed — confirm with the team
  • Yokohama
    Yokohama
    Site status: Not listed — confirm with the team
  • Yonago
    Yonago
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT02918318. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Placebo, Intranasal esketamine (28 mg), Intranasal esketamine (56 mg), Intranasal esketamine (84 mg). Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with depression; age range: From 20 Years to 64 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Janssen Pharmaceutical K.K., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me